NICE Overcomes UK Reimbursement Doubts Over Forxiga, US FDA Says No To Approval
Executive Summary
The health technology appraisal body for England and Wales now says Forxiga can help fill an unmet need for patients with inadequately controlled type 1 diabetes despite optimized insulin therapy. US regulators, meanwhile, have declined to approve the product for use in these patients.